INDEPENDENCE CONTRACT DRILLI (ICD) Stock Fundamental Analysis
NYSE:ICD - New York Stock Exchange, Inc. - US4534156066 - Common Stock - Currency: USD
ICD gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 61 industry peers in the Energy Equipment & Services industry. ICD may be in some trouble as it scores bad on both profitability and health. ICD does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
ICD had negative earnings in the past year.
ICD had a positive operating cash flow in the past year.
ICD had negative earnings in each of the past 5 years.
Of the past 5 years ICD 4 years had a positive operating cash flow.
1.2 Ratios
With a Return On Assets value of -15.80%, ICD is not doing good in the industry: 92.06% of the companies in the same industry are doing better.
ICD has a worse Return On Equity (-37.58%) than 87.30% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.8% | ||
| ROE | -37.58% | ||
| ROIC | N/A |
ROA(3y)-13.85%
ROA(5y)-15.34%
ROE(3y)-28.45%
ROE(5y)-28.56%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
In the last couple of years the Operating Margin of ICD has grown nicely.
With a decent Gross Margin value of 32.59%, ICD is doing good in the industry, outperforming 65.08% of the companies in the same industry.
In the last couple of years the Gross Margin of ICD has grown nicely.
The Profit Margin and Operating Margin are not available for ICD so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 32.59% |
OM growth 3YN/A
OM growth 5Y66.25%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y20.54%
GM growth 5Y2.72%
2. Health
2.1 Basic Checks
ICD does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ICD has been increased compared to 1 year ago.
Compared to 5 years ago, ICD has more shares outstanding
ICD has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -1.26, we must say that ICD is in the distress zone and has some risk of bankruptcy.
ICD has a Altman-Z score of -1.26. This is amonst the worse of the industry: ICD underperforms 88.89% of its industry peers.
The Debt to FCF ratio of ICD is 10.37, which is on the high side as it means it would take ICD, 10.37 years of fcf income to pay off all of its debts.
ICD has a Debt to FCF ratio (10.37) which is comparable to the rest of the industry.
ICD has a Debt/Equity ratio of 1.08. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 1.08, ICD is not doing good in the industry: 79.37% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.08 | ||
| Debt/FCF | 10.37 | ||
| Altman-Z | -1.26 |
ROIC/WACCN/A
WACC2.02%
2.3 Liquidity
A Current Ratio of 1.33 indicates that ICD should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.33, ICD is doing worse than 79.37% of the companies in the same industry.
A Quick Ratio of 1.28 indicates that ICD should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.28, ICD is not doing good in the industry: 66.67% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.33 | ||
| Quick Ratio | 1.28 |
3. Growth
3.1 Past
The earnings per share for ICD have decreased strongly by -662.07% in the last year.
Looking at the last year, ICD shows a very negative growth in Revenue. The Revenue has decreased by -21.60% in the last year.
The Revenue has been growing by 8.06% on average over the past years. This is quite good.
EPS 1Y (TTM)-662.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-942.86%
Revenue 1Y (TTM)-21.6%
Revenue growth 3Y36.07%
Revenue growth 5Y8.06%
Sales Q2Q%-23.12%
3.2 Future
The Earnings Per Share is expected to decrease by -46.50% on average over the next years. This is quite bad
Based on estimates for the next years, ICD will show a decrease in Revenue. The Revenue will decrease by -8.70% on average per year.
EPS Next Y-146.84%
EPS Next 2Y-46.5%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-20.87%
Revenue Next 2Y-8.7%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
ICD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ICD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
74.60% of the companies in the same industry are more expensive than ICD, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, ICD is valued cheaper than 100.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 0.54 | ||
| EV/EBITDA | 4.69 |
4.3 Compensation for Growth
A cheap valuation may be justified as ICD's earnings are expected to decrease with -46.50% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-46.5%
EPS Next 3YN/A
5. Dividend
5.1 Amount
ICD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
0.5858
-0.06 (-9.88%)
Chartmill FA Rating
GICS SectorEnergy
GICS IndustryGroupEnergy
GICS IndustryEnergy Equipment & Services
Earnings (Last)
Earnings (Next)
Inst Owners0.01%
Inst Owner Change0%
Ins Owners75.82%
Ins Owner Change0%
Market Cap8.92M
Analysts80
Price Target3.57 (509.42%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-26.38%
Min EPS beat(2)-50.58%
Max EPS beat(2)-2.18%
EPS beat(4)0
Avg EPS beat(4)-48.02%
Min EPS beat(4)-115.7%
Max EPS beat(4)-2.18%
EPS beat(8)4
Avg EPS beat(8)27.37%
EPS beat(12)5
Avg EPS beat(12)-68.42%
EPS beat(16)9
Avg EPS beat(16)-49.21%
Revenue beat(2)2
Avg Revenue beat(2)6.69%
Min Revenue beat(2)2.48%
Max Revenue beat(2)10.9%
Revenue beat(4)3
Avg Revenue beat(4)3.1%
Min Revenue beat(4)-3.06%
Max Revenue beat(4)10.9%
Revenue beat(8)6
Avg Revenue beat(8)2.51%
Revenue beat(12)8
Avg Revenue beat(12)2.8%
Revenue beat(16)9
Avg Revenue beat(16)0.49%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-48.55%
EPS NQ rev (3m)-25.02%
EPS NY rev (1m)-36.74%
EPS NY rev (3m)-10.78%
Revenue NQ rev (1m)-14.34%
Revenue NQ rev (3m)-18.05%
Revenue NY rev (1m)-3.15%
Revenue NY rev (3m)-5.96%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.05 | ||
| P/FCF | 0.54 | ||
| P/OCF | 0.21 | ||
| P/B | 0.06 | ||
| P/tB | 0.06 | ||
| EV/EBITDA | 4.69 |
EPS(TTM)-2.21
EYN/A
EPS(NY)-1.95
Fwd EYN/A
FCF(TTM)1.09
FCFY186.61%
OCF(TTM)2.86
OCFY487.46%
SpS11.83
BVpS10.37
TBVpS10.37
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.8% | ||
| ROE | -37.58% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 32.59% | ||
| FCFM | 9.24% |
ROA(3y)-13.85%
ROA(5y)-15.34%
ROE(3y)-28.45%
ROE(5y)-28.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5Y66.25%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y20.54%
GM growth 5Y2.72%
F-Score3
Asset Turnover0.48
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.08 | ||
| Debt/FCF | 10.37 | ||
| Debt/EBITDA | 4.57 | ||
| Cap/Depr | 58.68% | ||
| Cap/Sales | 14.9% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 116% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.33 | ||
| Quick Ratio | 1.28 | ||
| Altman-Z | -1.26 |
F-Score3
WACC2.02%
ROIC/WACCN/A
Cap/Depr(3y)80.67%
Cap/Depr(5y)71.77%
Cap/Sales(3y)20.36%
Cap/Sales(5y)19.39%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-662.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-942.86%
EPS Next Y-146.84%
EPS Next 2Y-46.5%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-21.6%
Revenue growth 3Y36.07%
Revenue growth 5Y8.06%
Sales Q2Q%-23.12%
Revenue Next Year-20.87%
Revenue Next 2Y-8.7%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-138.99%
EBIT growth 3YN/A
EBIT growth 5Y79.64%
EBIT Next Year42.05%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y162.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2030.36%
OCF growth 3Y494.79%
OCF growth 5Y30.47%